Caris Life Sciences, Inc. Q2 FY2026 earnings call

Overall Financial Performance

• GAAP gross margin expanded to 68%, up from 63% YoY and 65% Q1 2026
• Adjusted EBITDA of $55.7 million, with $28.5 million net cash from operations and $6.4 million positive free cash flow, marking the fifth consecutive quarter of positive adjusted EBITDA and free cash flow
• Cash and investments totaled $793 million at quarter end; a $100 million share repurchase program was authorized, with $18 million repurchased in Q2
• Blended average selling price (ASP) surpassed $3,850, a new company record

Commercial Operations

• Q1 2026 commercial realignment expanded territories from 82 to 146, with 290 commercial team members at quarter end (up from 270 in Q1), driving record sequential case growth of 6,400 cases
• Covered lives reached 239.5 million for MyCancerSeq and 131.9 million for Karis Assure, with continued payer access progress; ChromaSeq received first Medicare reimbursement at $3,228
• 74% of orders are now processed through EMR/portal, up from ~50% in Q1 2025, driving operational efficiency
• The Precision Oncology Alliance grew to 101 members with the addition of UC San Francisco and Northwell Health

Product Pipeline & Launches

• ChromaSeq: Heme therapy selection assay launched April 1, with Multi-X reimbursement secured
• MI Clarity V2: Digital breast cancer recurrence risk assay launched, with added chemotherapy and extended endocrine therapy decision support capabilities, launching an expanded version in H2 2026
• Karis Detect (multi-cancer early detection, MSED): Launched in June 2026, detects 58 cancer types from a single blood draw, with 83.9% of true positives resolved in one workup and 99.8% localized within two. The pipeline includes an end-to-end early interception strategy (called mutational cleanse: ultra-deep follow-up sequencing, AI-identified immunogenic mutations, and personalized peptide targets) to treat pre-clinical disease
• Minimal Residual Disease (MRD): Two complementary assays in development, with validation complete and launch planned for H2 2026; includes a tumor-naive assay for colorectal cancer and a tumor-informed pan-cancer assay with ultra-low sensitivity
• Clinical evidence continues to validate the company's comprehensive whole exome/transcriptome approach: two recent peer-reviewed studies confirmed the approach identifies more treatment-eligible patients and improves outcomes compared to small targeted gene panels
• Long-term expansion opportunity to non-oncology indications including cardiology, neurology, and autoimmune disease using the same core platform

Total company revenue for Q2 2026 was $263.7 million, a 45% year-over-year increase.

1. Molecular profiling services: Revenue of $252.3 million, representing 95.7% of total revenue, with 55% year-over-year growth. This segment includes 48,300 my-profile tissue cases (up 13% YoY, 11% sequentially) and 10,900 Karis Assure blood cases (up 50% YoY, 17% sequentially). Total clinical case volume grew 18% YoY to 59,200 cases.
2. Pharma R&D services: Revenue of $11.4 million, representing 4.3% of total revenue. Results reflected timing of deliverables, as the company prioritizes longer-term strategic partnerships over small one-time deals.

• Management raised full-year 2026 total revenue guidance to a range of $1.03 billion to $1.04 billion, representing 27% to 28% YoY growth, from the prior range of $1.00 billion to $1.02 billion. The upward revision is driven entirely by stronger than expected performance in the core molecular profiling business, with no revenue from Karis Detect included in guidance
• Full-year GAAP operating expense guidance is increased to $595 million to $600 million, from the prior $590 million to $595 million, to account for expanded commercial investment and launch marketing
• Management expects full-year 2026 GAAP net income to be positive, and full-year free cash flow to be positive: Q3 will use accumulated first-half cash to build inventory for Karis Detect, with free cash flow returning to positive in Q4 to deliver full-year positivity
• Clinical therapy selection volume growth is expected to reach 20% YoY in Q3 2026, and continue improving through Q4; the tissue/blood case mix is expected to remain steady at ~80/20, consistent with Q2
• Gross margins are expected to remain in the high 60% range for H2 2026, as the company prioritizes assay depth over near-term margin expansion, with long-term COGS reduction expected as volumes scale
• Adjusted EBITDA is expected to be $10 million to $16 million in Q3 (down from Q2 due to investments) before returning to Q2 levels in Q4, and remains positive for the full year
• PhRMA R&D full-year revenue guidance of $75 million to $80 million remains unchanged

• Near-term demand for Karis Detect may outpace current capacity, creating a risk of backlogs as the company scales up production
• It takes 6 to 9 months for new sales team members to fully ramp, which could create near-term productivity lags if expansion continues faster than expected
• FDA submission and approval timelines for new products, as well as future reimbursement updates, are uncertain and dependent on external regulatory agencies
• Clinical outcome data maturation for the tumor-naive MRD assay depends on unpredictable patient relapse rates, which could delay commercial launch timelines
• New product reimbursement approval timelines are uncertain, particularly for newer offerings like MI Clarity V2, which could impact near-term adoption
• Long-term competition in the precision oncology and liquid biopsy space could pressure market share or pricing if competitors accelerate their own commercial or technology development

Q: What drove the tissue volume reacceleration from Q1 to Q2, and what are the key areas for reinvestment in H2 2026, including updates on CapEx for lab expansion? / A: Volume acceleration (even excluding ~1,000 delayed Q1 cases) is driven by the sales team realignment completed in Q1, with reps now fully acclimated to their new territories. Most H2 reinvestment will go toward building inventory ahead of expected Karis Detect demand, which increased $47 million sequentially in Q2. CapEx will continue for additional sequencing capacity from new suppliers, with $15 to $20 million expected in Q3. Free cash flow is expected to be neutral after nine months, with Q3 spending funded by first-half cash, then returning to positive in Q4.

Q: What is the commercial launch timeline for MRD, and how could adding new sequencing suppliers change long-term test economics? / A: MRD validation is complete, with launch planned for the back half of 2026. New competing sequencing suppliers offer higher throughput and significantly lower per-test costs than the long-standing incumbent, which will allow Karis to simultaneously increase total capacity and lower cost of goods sold for all products over the long term.

Q: What is your outlook for competitive positioning in precision oncology, and how do you see the market opportunity evolving? / A: Precision oncology is still in early innings, with a large and growing total addressable market as institutions build out new precision oncology programs. Customer demand is shifting toward comprehensive genomic profiling rather than narrow panels, which plays directly to Karis' long-standing whole exome/transcriptome depth strategy. Karis' position as both a clinical and research partner through the Precision Oncology Alliance gives it a strong competitive advantage, and the company has the financial flexibility to continue investing to capture market share.

Q: What is the commercial and capacity outlook for Karis Detect, including channel strategy and DTC marketing plans? / A: Karis is planning an aggressive national DTC advertising campaign that will launch in the next few months. Detect will mostly be distributed through channel partners like EverlyWell, with very few of Karis' own sales reps dedicated directly to the product. Current annual capacity is ~$1 billion in revenue, and the company is expanding to ~$3 billion in annual capacity, though management still acknowledges demand could outpace supply leading to near-term backlogs.